This company listing is no longer active
ASLN Stock Overview
A clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ASLAN Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.60 |
| 52 Week High | US$22.16 |
| 52 Week Low | US$0.47 |
| Beta | 1.4 |
| 11 Month Change | -76.33% |
| 3 Month Change | -83.52% |
| 1 Year Change | -97.26% |
| 33 Year Change | -99.46% |
| 5 Year Change | -99.52% |
| Change since IPO | -99.73% |
Recent News & Updates
Shareholder Returns
| ASLN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -76.5% | -0.7% | -1.6% |
| 1Y | -97.3% | 19.8% | 30.8% |
Return vs Industry: ASLN underperformed the US Biotechs industry which returned 11.4% over the past year.
Return vs Market: ASLN underperformed the US Market which returned 19.4% over the past year.
Price Volatility
| ASLN volatility | |
|---|---|
| ASLN Average Weekly Movement | 21.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ASLN's share price has been volatile over the past 3 months.
Volatility Over Time: ASLN's weekly volatility has decreased from 31% to 22% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 35 | Carl Alan Jason Firth | aslanpharma.com |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd.
ASLAN Pharmaceuticals Limited Fundamentals Summary
| ASLN fundamental statistics | |
|---|---|
| Market cap | US$1.70m |
| Earnings (TTM) | -US$35.03m |
| Revenue (TTM) | US$12.00m |
0.1x
P/S Ratio0.0x
P/E RatioIs ASLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASLN income statement (TTM) | |
|---|---|
| Revenue | US$12.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$12.00m |
| Other Expenses | US$47.03m |
| Earnings | -US$35.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.38 |
| Gross Margin | 100.00% |
| Net Profit Margin | -291.89% |
| Debt/Equity Ratio | -147.6% |
How did ASLN perform over the long term?
See historical performance and comparison